---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-003781"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:32:20.715690+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Invivyd announces PEMGARDA neutralizes dominant SARS-CoV-2 variant XEC in vitro

## Summary
- New data show PEMGARDA (pemivibart) maintains neutralizing activity against XEC, which with KP.3.1.1 accounts for 69% of U.S. variants per CDC.
- Data submitted to FDA; update to PEMGARDA Fact Sheet for Healthcare Providers expected.
- Pemivibart has shown consistent activity across 39 distinct SARS-CoV-2 variants over nearly three years.
- Company does not anticipate meaningful change to neutralization if epitope remains intact as since Omicron BA.1.

## SEC filing metadata
- accession: 0000950170-25-003781
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000095017025003781/0000950170-25-003781-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000095017025003781/ivvd-20250110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-003781
- JSON: https://secwatch.observer/filing/0000950170-25-003781.json
- Plain text: https://secwatch.observer/filing/0000950170-25-003781.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.